Literature DB >> 29794830

Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection.

Marshall J Glesby1, David B Hanna2, Donald R Hoover3, Qiuhu Shi4, Michael T Yin5, Phyllis C Tien6, Mardge Cohen7, Kathryn Anastos2,8, Anjali Sharma8.   

Abstract

OBJECTIVE: The aim of this study was to determine the associations between visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) mass with homeostatic model assessment-insulin resistance (HOMA-IR) and incidence of diabetes mellitus in women with and without HIV infection.
DESIGN: Cross-sectional design for associations between abdominal fat and HOMA-IR; longitudinal design for associations between abdominal fat and incident diabetes.
METHODS: We assessed associations between dual X-ray absorptiometry scan-derived VAT and SAT with HOMA-IR in a subsample from the Women's Interagency HIV Study (n = 226 with and n = 100 without HIV) using linear regression. We evaluated associations of VAT, SAT and HOMA-IR with incident diabetes mellitus using Cox proportional hazards models.
RESULTS: VAT mass was positively associated with log HOMA-IR in fully adjusted linear regression models stratified by HIV serostatus, including adjustment for SAT. During median follow-up of 10.6 years, incidence of diabetes was 1.63 [95% confidence interval (95% CI) 1.15-2.31] and 1.32 [95% CI 0.77-2.28] cases per 100 person-years in women with and without HIV (P = 0.52). In a fully adjusted model, baseline VAT (hazard ratio 2.64 per kg; 95% CI 1.14-6.12; P = 0.023) and SAT (hazard ratio 1.34 per kg; 95% CI 0.73-2.45; P = 0.35) were associated with incident diabetes, but the latter was not statistically significant.
CONCLUSION: VAT mass was independently associated with HOMA-IR in women with and without HIV and was independently associated with future development of diabetes.

Entities:  

Mesh:

Year:  2018        PMID: 29794830      PMCID: PMC6084460          DOI: 10.1097/QAD.0000000000001873

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  38 in total

1.  The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

Authors:  H Murata; P W Hruz; M Mueckler
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

2.  Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs.

Authors:  Susana Araujo; Sara Bañón; Isabel Machuca; Ana Moreno; María J Pérez-Elías; José L Casado
Journal:  Eur J Endocrinol       Date:  2014-08-12       Impact factor: 6.664

3.  Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

Authors:  Jacqueline Capeau; Vincent Bouteloup; Christine Katlama; Jean-Philippe Bastard; Vincent Guiyedi; Dominique Salmon-Ceron; Camelia Protopopescu; Catherine Leport; Francois Raffi; Geneviève Chêne
Journal:  AIDS       Date:  2012-01-28       Impact factor: 4.177

4.  New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes.

Authors:  Opass Putcharoen; Lalita Wattanachanya; Jiratchaya Sophonphan; Sarawut Siwamogsatham; Vorapot Sapsirisavat; Sivaporn Gatechompol; Supalak Phonphithak; Stephen J Kerr; Pairoj Chattranukulchai; Yingyos Avihingsanon; Kiat Ruxrungtham; Anchalee Avihingsanon
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

5.  Visceral adiposity, fasting plasma insulin, and blood pressure in Japanese-Americans.

Authors:  E J Boyko; D L Leonetti; R W Bergstrom; L Newell-Morris; W Y Fujimoto
Journal:  Diabetes Care       Date:  1995-02       Impact factor: 19.112

6.  Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

Authors:  Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown
Journal:  Clin Infect Dis       Date:  2016-01-20       Impact factor: 9.079

7.  Association of lymphocyte sub-populations with clustered features of metabolic syndrome in middle-aged Japanese men.

Authors:  Takeshi Tanigawa; Hiroyasu Iso; Kazumasa Yamagishi; Isao Muraki; Noriyuki Kawamura; Akinori Nakata; Susumu Sakurai; Tetsuya Ohira; Takashi Shimamoto
Journal:  Atherosclerosis       Date:  2004-04       Impact factor: 5.162

8.  Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.

Authors:  Carlos Lorenzo; Anthony J Hanley; Steven M Haffner
Journal:  Diabetologia       Date:  2013-10-19       Impact factor: 10.122

9.  Comparison of Insulin Resistance to Coronary Atherosclerosis in Human Immunodeficiency Virus Infected and Uninfected Men (from the Multicenter AIDS Cohort Study).

Authors:  Michael I Brener; Wendy S Post; Sabina A Haberlen; Long Zhang; Frank J Palella; Lisa P Jacobson; Adrian S Dobs; Richard T George; Mallory D Witt; Matthew Budoff; Lawrence A Kingsley; Todd T Brown
Journal:  Am J Cardiol       Date:  2015-12-31       Impact factor: 2.778

10.  Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010.

Authors:  Alfonso C Hernandez-Romieu; Shikha Garg; Eli S Rosenberg; Angela M Thompson-Paul; Jacek Skarbinski
Journal:  BMJ Open Diabetes Res Care       Date:  2017-01-05
View more
  2 in total

1.  Intestinal Dysbiosis and Markers of Systemic Inflammation in Viscerally and Generally Obese Persons Living With HIV.

Authors:  Lasha Gogokhia; Ying Taur; Krishna Juluru; Neda Yagan; Yuan-Shan Zhu; Eric Pamer; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2020-01-01       Impact factor: 3.771

2.  Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era.

Authors:  Robert S Rosenson; Demetria Hubbard; Keri L Monda; Stephanie R Reading; Ligong Chen; Paul J Dluzniewski; Greer A Burkholder; Paul Muntner; Lisandro D Colantonio
Journal:  J Am Heart Assoc       Date:  2019-12-27       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.